New drug cocktail aims to tame aggressive breast cancer
NCT ID NCT03742102
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advanced or metastatic TNBC will receive different drug combinations to see how well they shrink tumors and what side effects occur. The goal is disease control, not a cure, as ongoing management is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Tucson, Arizona, 85715, United States
-
Research Site
Columbia, Maryland, 21044, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Grand Rapids, Michigan, 49503, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Dallas, Texas, 75246, United States
-
Research Site
Williamsburg, Virginia, 23188, United States
-
Research Site
Kelowna, British Columbia, V1Y 5L3, Canada
-
Research Site
London, Ontario, N6A 4L6, Canada
-
Research Site
Greenfield Park, Quebec, J4V 2H1, Canada
-
Research Site
Montreal, Quebec, H4A 3J1, Canada
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Krakow, 31-501, Poland
-
Research Site
Lublin, 20-090, Poland
-
Research Site
Opole, 45-060, Poland
-
Research Site
Rzeszów, 35-021, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Warsaw, 04-141, Poland
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Kaohsiung City, 80756, Taiwan
-
Research Site
Taichung, 40447, Taiwan
-
Research Site
Tainan, 70403, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taipei, 112, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
London, EC1M 6BQ, United Kingdom
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- Freezing tumors to supercharge immunotherapy: new hope for aggressive breast cancer?
- New antibody drug aims to unleash immune system on Hard-to-Treat cancers
- Immunotherapy avelumab aims to stop triple negative breast cancer recurrence
- New drug combo takes on advanced cancers in early trial
- New drug combo aims to keep advanced breast cancer in check